Objective: The aim of this study was to assess the efficacy of TU-025, keishibukuryogan, a Japanese prescription herbal medicine used for hot flash management, in American women.
P
ostmenopausal hormone therapy has well-documented positive effects on vasomotor symptoms, sleep quality, and even sexual functioning. However, many postmenopausal women are concerned about the US Food and Drug Administration (FDA) boxed warning regarding a slight but statistically significant increased risk of substantial harms including dementia 1,2 breast cancer, [3] [4] [5] endometrial cancer, 6 venous thromboembolism, 7 and gallbladder disease. 8 The 2010 North American Menopause Society position statement on postmenopausal hormone therapy addresses these concerns and, based on clinical data, supports the use of hormone therapy during menopause to treat significant symptoms or reduce significant risk of fractures. 9 The Society notes that the potential therapeutic benefits and risks needed to be considered. For symptomatic women concerned about a potentially increased risk of atypical ductal hyperplasia, 10 estrogen receptorY positive breast cancer, 11 and node-positive breast cancer, 12 there is great interest in nonhormonal options.
In Japan, more than 90% of Japanese gynecologists prescribe traditional Japanese multiherb medicinal formulas for women's health concerns including menopause. 13, 14 Termed Kampo, these formulas are regulated as prescription pharmaceutical drugs by the Japanese Ministry of Health and have been covered by the national healthcare plan for more than 25 years.
The 1,800-year-old formula termed keishibukuryogan, whether known as TJ-25 (the Japanese identifier) or TU-025 (the US identifier), is one of the foremost Kampo agents used for perimenopausal hot flash management in Japan. Keishibukuryogan consists of cinnamon bark (Cinnamomum cassia Blume), peony root (Peonia lactiflora Palls), peach kernel (Prunus persica Batsch), poria sclerotium (Poria cocos Wolf), and moutan bark (Peonia suffuticosa Andrews). The active ingredient(s) is not known. Synergistic interactions are presumed based on historical record and experience.
Kampo agents meet the stringent Japanese standards for product manufacturing, consistency, and stability. Postmarketing surveillance data obtained from the Japanese Ministry of Health and Welfare and Tsumura & Company demonstrated that TJ-25 used in Japan has an estimated adverse event rate of 0.00356% for the 128,435,263 doses provided to 701,832 unique women treated for an average of 6 months during a period of 9 years.
Studies conducted using state-of-the-art approaches have demonstrated that TJ-25 has no estrogenic activity. Noguchi et al 15, 16 in Japan have developed an animal model of menopausal hot flashes focusing on calcitonin geneYrelated peptide (CGRP). Animal model in vivo interventions of TJ-25 result in an equivalence of TJ-25 compared with estrogen in suppressing CGRP-induced hot flashes with no evidence of estrogenic activity. 17 In addition, in the same animal model, TJ-25 inhibits the synthesis and release of CGRP. 18 Given these mechanistic considerations, we conducted a randomized, double-blind, placebo-controlled, modified phase II trial that enrolled healthy postmenopausal American women to determine the impact of TU-25 on postmenopausal symptoms.
METHODS

Design
The study was of 12-weeks duration plus a 1-week placebo lead-in period. Postmenopausal was defined as (1) no menses for consecutive 12 months, or (2) previous hysterectomy without oophorectomy and follicle-stimulating hormone (FSH) levels of 40 mIU/mL or higher and estradiol levels of 20 pg/mL or lower, or (3) 2 months past surgery for hysterectomy with oophorectomy. Inclusion criteria included vasomotor symptoms documented by the Mayo Hot Flash Symptom Diary scoring system: mild (1), moderate (2), severe (3), and very severe (4), for a total score of 28 or greater in a week (ie, two moderately severe hot flashes/d = 14/wk Â 2 = 28 score or 4 mild/d = 4 Â 7 = 28). Other criteria included willingness to take an herbal formula, no hormone therapy for 8 weeks, smoking of less than 10 cigarettes/day, body mass index (BMI) less than 36 kg/m 2 , Beck Depression Inventory score of less than 11, and not currently taking antidepressant medication. Women with a history of breast or uterine cancer were excluded; however, for other cancers, individuals were eligible if they were cancer-free for 5 years.
No pharmacokinetic data on the multiple potentially active ingredients in keishibukuryogan exist. For this reason, regular dosing was defined as the dose amount provided on a prescription basis to women in Japan (7.5 g/d). To assess for a possible dose-response in larger-sized American women, we included a higher-dose arm of 12.5 g/day. Participants were block randomized to receive one of three treatment protocols: (1) TU-025 at 7.5 g/day, (2) TU-025 at 12.5 g/day, or (3) placebo. Five tablets of the product were taken twice a day for 12 weeks. Participants were seen monthly for compliance, adverse effects, laboratory monitoring, and outcome measures. Tsumura & Company (Tokyo, Japan) provided the product and placebo in a capsule form. A separate research pharmacy service distributed placebo and active medication that were identical in appearance and odor. All participants took placebo for 1 week after enrollment before active medication was provided.
The study was approved by the University of Minnesota Research Subjects' Protection Program. All methodologies were reviewed and approved by the FDA under their Investigational New Drug policies. The study was registered at ClinicalTrials.gov (NCT00119418).
Sample
From more than 2,200 inquiries, 178 healthy postmenopausal women were recruited and enrolled from the Minneapolis, St. Paul metropolitan area, through newspaper, radio, and television coverage.
Procedure
The women were randomized in blocks using a pseudorandom number that was used to assign the participants, as they were enrolled in the study, to the placebo, low-dose, or high-dose groups. The randomization schedule was sent to the research pharmacy to prepare containers for administration to the study participants. All investigators and research staff were blinded to the group assignment. The randomization and all analyses were conducted using SAS System software.
Analysis followed the intention-to-treat guidelines. Data were analyzed using general linear mixed model methods and the generalized linear mixed model methods approach.
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The outcomes were analyzed as either a continuous variable or a categorical variable when there were clinically accepted cutpoints for the measurement. For the continuous variable outcomes (the hot flash scale score, the Greene Climacteric Index [GCI] , and the Pittsburgh Sleep Quality Scale [PSQI]), we used the PROC MIXED procedure in the SAS System software. For categorical outcomes (hot flash scale score Q28 points), the PROC GENMOD and GLIMMIX procedures were used.
For efficacy analysis, the average daily hot flash score was weighted based on the number of mild symptoms plus twice the number of moderate hot flashes plus three times the number of severe hot flashes plus four times the number of very severe hot flashes recorded in a given week divided by the number of days. For the primary efficacy analysis, changes in the hot flash score and the number of hot flashes were summarized as the change in percentage from the baseline.
The type 3 test of fixed effect provided the F statistic, degrees of freedom, and P values for the effects of the treatment group, month, and treatment group by month. The difference of differences in the means was tested using the latter interaction term.
Statistical power analysis was based on the published data of Loprinzi et al 22 on self-reported frequency and severity of hot flash symptoms with interventions. For the within-group SD for Composite Hot-flash Score, we used the SEM and sample size for the placebo group from the paroxetine randomized controlled trial by Stearns et al. 23 Based on their data, we estimated the SD for the Composite Hot-flash Score as 8.76. For statistical power, we assumed a 5% level of significance and a 90% power for detecting a true group by level difference. We assumed 10% attrition in the study. Based on these assumptions, the study was adequately powered with 60 enrolled participants for each of the three study arms.
Measures
The study included three primary efficacy variables: (1) the frequency and severity of hot flash symptoms, (2) climacteric symptoms, and (3) sleep quality. The daily Mayo Hot Flash Symptom Diary was used for determining the frequency and severity of hot flashes. 22, 24 The daily diary was brought at each monthly visit. The score was aggregated and summarized as a daily average number of hot flashes and hot flash scored based on frequency and severity. Climacteric or menopausal symptoms were summarized using the GCI. 25, 26 Sleep quality was assessed using the PSQI. 27, 28 For the eight PSQI scales, the overall sleep quality and overall indices were treated as the primary outcomes. The GCI and PSQI questionnaires were completed in clinic at baseline and at 1, 2, and 3 months after enrollment. Adherence was evaluated by pill counts at each visit. Liver function tests and complete blood counts were obtained at each visit. Hormone measurements were obtained before enrollment and at the end of participation. After the last woman completed the study, all participants were contacted by telephone and asked to guess their treatment group assignment.
RESULTS
From the 265 women seen at intake and evaluated for inclusion in the study, the final study included 178 eligible women. (Fig. 1 ) Eighty-seven individuals were excluded because of the following reasons in order of frequency: (1) a Table 1 shows the demographic characteristics of the women enrolled. Participants were nearly evenly divided between the three groups. The groups were comparable with one another in terms of age, racial status, marital status, and educational level. None of the observed differences in characteristics was statistically significant across the study groups. On average, the women enrolled were in their early 50s (age, 53.6 y), white, married, and well educated.
Approximately 80% of the women experienced natural menopause (Table 2 ). Based on medical histories obtained, one in nine of the women (12.4%) had had a bilateral oophorectomy. There were no statistically significant differences between the groups in terms of their medical history. Table 3 shows the core physical findings for these women at baseline. Overall, most of the women enrolled were either slightly overweight or obese. The mean BMI for these women was 26.1 kg/m 2 . Between the intervention conditions, there were no statistically significant differences in these core physical findings at the time of intake.
Baseline estradiol and FSH levels are shown in Table 4 . No statistically significant differences exist between the intervention conditions. Approximately three in five women were found to have estradiol levels less than 21 pg/mL, and three in four women had FSH levels greater than or equal to 60 mIU/mL. These levels are consistent with those found among women at menopause.
Figures 2 and 3 summarize the mean hot flash diary scores at baseline and at 1, 2, and 3 months. Figure 2 depicts the change and percentage change in the average monthly hot flash scores. Figure 3 depicts the change and percentage change in the numbers of hot flashes at monthly visits. At 3 months, the results from the hot flash scores showed a decrease in all three groups: 34% in the placebo group, 40% in the 7.5 g/day group, and 38% in the 12.5 g/day group. Although these declines in mean scores were significant (P G 0.001) within each group, the differences between groups were not statistically significant (P = 0.990).
The mean scores for the GCI, which includes Depression, Anxiety, Psychosocial, Somatic, Vasomotor, and Sexual Dysfunction Indexes, declined significantly across the study (all P values G 0.001). However, no statistically significant treatment group by month interaction was observed. The PSQI and its associated subscales demonstrated a statistically significant attenuation in all scores for all the participants across the study (all P values G 0.001), except for sleep medication use, which remained constant across the study. The Beck Depression Inventory summarized at intake and conclusion demonstrated some improvement in mood (P = 0.044), with no significant differences between treatment groups (data not shown).
Twenty-five women (14.0%) withdrew before completing the 12-week study. There were no statistically significant differences in the likelihoods of withdrawing across the treatment conditions (W 2 = 4.12; df = 2; P = 0.127). The primary reason for withdrawal was diarrhea (15/25) followed by persistent hot flashes (6/25) . Diarrhea was present in approximately 20% of the participants receiving active medication (Table 5 ). This diarrhea was statistically significantly more prevalent in the low-dose and high-dose groups compared with the placebo group (W 2 = 12.05; df = 2; P = 0.002).
DISCUSSION Despite supportive animal model data in peer-reviewed literature as well as the widespread use of prescription TJ-25 in Japan for perimenopausal women, this rigorous randomized controlled trial failed to demonstrate the efficacy of TU-025 beyond placebo for reducing the severity and frequency of hot flash symptoms, climacteric symptoms, or disrupted sleep symptoms in postmenopausal American women. Failure to find a treatment benefit was unlikely to be related to breaches in study protocol, participant adherence, statistical power, and length of follow-up.
Despite the use of a 1-week placebo lead-in period to minimize the enrollment of placebo responders and despite the additional 12 weeks of study duration, clinically significant reductions in hot flash severity and frequency were experienced in a significant portion of the women receiving placebo. The 34% rate of placebo response is consistent with that reported in other clinical trials. However, the placebo effect was expected to resolve before 12 weeks of therapy. Future herbal medicine trials should measure participant expectations at the time of enrollment. In this study, several participants noted afterward that they enrolled to Bprove[ that herbal medicines work. This suggests the presence of a significant meaning response. 29 Unlike the study of a single Western herb with candidate marker ingredients for monitoring serum levels, the translation of a unique healing system, such as Kampo diagnoses and therapeutics, into a Western model is faced with limitations that may have not been appreciated. Despite the strengths of the study, three methodological concerns are important to recognize for future trials of a products taken out of their wholesystem context.
The first concern is the selection of the study population. Following the FDA guidelines, we restricted the entrance into this study to women who had experience cessation of menses for more than 1 year. This meant that many women who requested enrollment were excluded. Traditional Kampo practitioners do not include a women's menstrual status in formula decisions. In addition, women with depressed mood as determined by Beck Depression Inventory scores (911) were excluded from the study and requested to work with a physician regarding the possibility of depression. The reasoning was that women at risk for significant depression should not be enrolled when proven effective antidepressant therapy that also addressed hot flashes was already available. We did not realize that nearly 100% of these women refused to consider the prescription of antidepressant therapy and attributed their depressive symptoms to severe life disruption by hot flashes/night sweats. Exclusions because of menopause status or an elevated depression score may have introduced bias in enrollment.
Second, inclusion criteria did not consider the traditional Kampo assessments of each participant's sho or constitutional state. Although completely contrary to Kampo practice, every woman who met the FDA entrance criteria was enrolled into the study. Per Kampo tradition, keishibukuryogan is best (14.6) matched to women with hiesho (subjective coldness) and ouketsu (metaphoric blood stagnation). Women with a qi stagnation pattern, for example, would be more likely to respond to another commonly used formula, kamishoyosan.
The substantially more dropouts in the treated rather than the placebo group suggests that a problem existed with the treatment itself in American women. The prominent diarrhea noted by 20% of American women receiving TU-025 at approximately 6 weeks of treatment is consistent with a constitutional state and formula mismatch. A third concern is the appropriate dosing of the product. TU-025, keishibukuryogan, does not have active marker ingredients for monitoring. In the absence of pharmacokinetic data and monitoring capacities, no rational guidance for determining total dose and dose frequency required for a nonJapanese population exists. Dosing for this study was based on extrapolation from Japanese tradition adopted for American women with distinct preference for twice-a-day pill dosing and a higher mean BMI. Although a higher total dose was used in one arm, the dose may not have been sufficient or sufficiently frequent to effect a change.
Future trials of traditional Asian medicines will need to consider these three concerns. Most importantly, however, for future trials, Watanabe et al 30 have recently proposed two innovative methodologies that would include the use of both Western and Kampo diagnoses with randomization and placebo controls. These new methodologies not only may meet the FDA requirements for generalizable inclusion criteria but would also match traditional clinical assessments and treatments. Future studies on one of these templates should be developed. In addition, because pharmacokinetic data cannot be developed on formulas without a known, single active ingredient, smaller preliminary dose-escalation trials may be necessary to develop rational dosing guidelines.
CONCLUSIONS
Unlike clinical experience in Japan, for American women, the use of a standardized 1,800-year-old traditional Japanese multiherb formula, termed kesihibukuryogan, or TU-025, did not significantly reduce the frequency and severity of hot flash symptoms, improve climacteric symptoms, or benefit sleep quality. Also, unlike clinical experience in Japan, significant diarrhea developed in 20% of participants receiving the active agent. Despite the use of a 1-week placebo lead-in to minimize placebo response, the placebo agent significantly reduced hot flash severity and frequency. This study identified several potentially significant methodological factors unique to the scientific study of a traditional herbal formula to be considered in future assessments of traditional Asian medicines.
